# Effect of Loratadine in Lymphangioleiomyomatosis

> **NCT05190627** · PHASE2 · UNKNOWN · sponsor: **Institut d'Investigació Biomèdica de Bellvitge** · enrollment: 62 (estimated)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Loratadine
- **DRUG:** Placebo 10mg/day added to rapamycin for 12 months

## Key facts

- **NCT ID:** NCT05190627
- **Lead sponsor:** Institut d'Investigació Biomèdica de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190627, "Effect of Loratadine in Lymphangioleiomyomatosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05190627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*